BioPharma Credit PLC Notice of Results (9384O)
August 24 2017 - 9:15AM
UK Regulatory
TIDMBPCR
RNS Number : 9384O
BioPharma Credit PLC
24 August 2017
24 August 2017
BIOPHARMA CREDIT PLC
("BPC" or the "Group")
NOTICE OF RESULTS - PLEASE NOTE NEW TIMINGS FOR THE MEETING
BioPharma Credit PLC (LSE: BPC), the life sciences debt
investment trust, will announce its audited Half Year Results for
the period ending 30 June 2017, on Thursday 21 September 2017.
A management presentation will be held at 10:30 at Goldman
Sachs, Peterborough Court, 133 Fleet Street, London EC4A 2BB. A
conference call facility will also be available.
To confirm your attendance, or request conference call details,
RSVP to tmitchell@bellpottinger.com by Wednesday 13 September
2017.
-Ends-
For further information, please contact:
BioPharma Credit
Alex v. Perfall (Royalty
Pharma)
Jeff Caprio (Pharmakon
Advisors) +1 (212) 883 2263
J.P. Morgan Cazenove
William Simmonds
Oliver Kenyon +44 (0)20 7742 4000
Goldman Sachs
Shomick Bhattacharya
Charlie Lytle
Tom Hartley +44 (0)20 7774 1000
Bell Pottinger
David Rydell
Ian Shackleton +44 (0)20 3772 2602
About BioPharma Credit:
Shares of BioPharma Credit PLC were successfully admitted to
trading on the Specialist Fund Segment of the Main Market of the
London Stock Exchange on 27 March 2017: one of the largest IPO's in
the London market this year with a market capitalisation just under
$800m. Gross proceeds included a portfolio of $338.6 million in
seed assets, comprised of loans secured by royalties and other cash
flows from sales of close to 30 life sciences products.
The company provides investors with an opportunity to gain
uncorrelated returns and exposure to the fast-growing life sciences
industry, through a diversified portfolio of loans and other
instruments backed by royalties or other cash flows derived from
sales of approved life sciences products.
BioPharma Credit's primary objective is to generate predictable
income for shareholders over the long term. Once substantially
invested, BioPharma Credit will target an annual dividend yield of
7 per cent. (calculated by reference to the Issue Price), and a net
total return on NAV of 8 to 9 per cent. per annum in the medium
term. Pharmakon Advisors, the fund's Investment Manager, was
founded in 2009 and has invested US$1.3 billion in 20 transactions
across four funds. The first three funds are now fully invested.
Drawing upon the expertise and successful track record of Pharmakon
Advisors, the fund enjoys access to its extensive, life sciences
industry-focused knowledge and contacts to source, analyse and
structure attractive debt investments.
Through a shared services agreement with Royalty Pharma, founded
in 1996, the Investment Manager will be able to rely on the
complementary expertise of the team behind the market leading
investor in pharmaceutical royalties.
More details are available on www.bpcruk.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORMMGZRDDFGNZM
(END) Dow Jones Newswires
August 24, 2017 10:15 ET (14:15 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2023 to May 2024